Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies

Journal of Cancer Research and Clinical Oncology

Volumn 124, Issue 3-4, 1998, Pages 207-214

  Kollmannsberger, C ^a   Hartmann, J T ^a   Kanz, L ^a   Bokemeyer, C ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Allogenic bone marrow transplantation; Autologous bone marrow transplantation; Etoposide; Etoposide related leukemia; High dose chemotherapy; Peripheral stem cell transplantation; Secondary leukemia; Secondary myelodysplastic syndrome

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CHLORMETHINE; CYCLOPHOSPHAMIDE; EPIPODOPHYLLOTOXIN DERIVATIVE; FLUOROURACIL; METHOTREXATE; PREDNIMUSTINE;

ACUTE GRANULOCYTIC LEUKEMIA; AGE; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; FOLLOW UP; HODGKIN DISEASE; HUMAN; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SECOND CANCER; SPLENECTOMY; STEM CELL TRANSPLANTATION; TESTIS CANCER;

ACUTE DISEASE; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID; MYELODYSPLASTIC SYNDROMES; NEOPLASMS; NEOPLASMS, SECOND PRIMARY;

EID: 0031978239     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004320050156     Document Type: Article

References (54)

1. Alterini R, Rigacci L, Magrini S, Cellai E, Masala G, Seniori Costantini A, Spediacci M, Bagnoli R, Innocenti E, Stefanacci S, Bellesi G, Rossi Ferrini P, Biti G (1997) Second malignant neoplasms after Hodgkin's disease (HD): an analysis of 1524 patients (pts) treated in Florence (1960-1991). Proc Am Soc Clin Oncol: 26a (abstract 58)
2. Andrieu JM, JFrah N, Payen C, Fermanian J, Coscas Y, Flandrin G (1990) Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with ropp chemotherapy for Hodgkinic disease. J Clin Oncol 8:1148-1154
3. Armitage J, Vose J, Anderson J, Bierman P, Bishop M, Kessinger A (1993) Complete remission (CR) following high-dose chemotherapy (HDC) and autologous hematopoietic rescue for non-Hodgkin's lymphoma: a valuation of CR-durability and incidence of secondary myelodysplastic syndrome. Proc Am Soc Clin Oncol 12:363 (abstract 1225)
4. Bajorin D, Motzer R, Rodriguez E, Murphy B, Bosl G (1993) Acute nonlymphocytic leukemia in germ-cell tumor patients treated with etoposide-containing chemotherapy. J Natl Cancer Inst 85:60-62
5. Bhatia S, Ramsay N, Steinbuch M, Dusenberg K, Shapiro R, Weisdorf D, Robinson L, Miller J, Neglia J (1996) Malignant neoplasms following bone marrow transplantation. Blood 87:3633-3639
6. Boivin JF, Hutchinson GB, Zauber AG, Bernstein L, Davis FG, Michel RP, Zanke B, Tan CT, Fuller LM, Mauch P, Ultman LE (1995) Incidence of second cancers in patients treated for Hodgkin's disease. J Natl Cancer Inst 87:732-741
7. Bokemeyer C, Schmoll HJ (1993) Secondary neoplasms following treatment of malignant germ cell tumors. J Clin Oncol 11:1703-1709
8. Bokemeyer C, Schmoll HJ, Poliwoda H (1994) Sekundäre Leukämien nach Etoposid-haltiger Chemotherapie. Dtsch Med Wochenschr 119:707-713
9. Bokemeyer C, Kuczk M, Beyer J, Siegert W (1995) Risk of secondary leukemia following high cumulative doses of etoposide during chemotherapy for testicular cancer. J Natl Cancer Inst 87:58-59
10. Boshoff C, Begent RH, Oliver RT, Rustin GI, Newlands ES, Andrews R, Shelton M, Holden L, Ong J (1995) Secondary tumours following etoposide containing therapy for germ cell cancer. Ann Oncol 6:35-40
11. Cheson B, Vena D, Freidlin B, Barrett J, Sorensen J (1997) The risk of secondary malignancies following purine analog therapy of chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL). Proc AM Soc Clin Oncol 15a (abstract 52)
12. Coltman CA, Dixon DO (1982) Second malignancies complicating Hodgkin's disease: a Southwest Oncology Group 10-year follow-up. Cancer Treat Rep 66:1023-1033
13. Curtis RE, Boice JD, Stovall M, Bernstein L, Greenberg RS, Flannery JT, Schwartz AG, Weyer P, Moloney WC, Hoover RN (1992) Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 326:1745-1751
14. Darrington D, Vose J, Andersen J, Bierman P, Bishop M, Chan W, Morris M, Reed E, Sanger W, Tarantolo S, Weisenburger D, Kessinger A, Armitage J (1994) Incidence and characterisation of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 12:2527-2534
15. DeCillis A, Anderson S, Wickerham D, Brown A, Fisher B (1997) Acute myeloid leukemia (AML) in NSABP B25. Proc Am Soc Clin Oncol 130a (abstract 459)
16. Diamandidou E, Buzdar A, Smith T, Frye D, Witjahsono M, Hortobogyi G (1996) Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy. The University of Texas M. D. Anderson Cancer Center experience. J Clin Oncol 14:2722-2730
17. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glich IH, Coltman CA Jr, Miller TP (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1008
18. Gomez GA, Aggarwal KK, Han T (1982) Post-therapeutic acute malignant myeloproliferative syndrome and acute nonlymphocytic leukemia in non-Hodgkin's lymphoma. Cancer 50: 2285-2288
19. Greene MH, Hoover RN, Fraumeni JF Jr (1978) Subsequent cancer in patients with chronic lymphocytic leukemia a possible immunologic mechanism. J Natl Cancer Inst 61:337-340
20. Greene MH, Young RC, Merrill LM, DeVita VT (1983) Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy for non-Hodgkin's lymphoma. Cancer Res 3:1891-1898
21. Greene MH, Boice JD, Greer BE, Blessing JA, Dembo AJ (1982) Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer. N Engl J Med 307:1416-1421
22. Henry-Amar M (1992) Second cancer after the treatment for Hodgkin's disease: a report from the international database on Hodgkin's disease. Ann Oncol 3 [Suppl 4]:117-121
23. Henry-Armar M, Dietrich PY (1993) Acute leukemia after the treatment of Hodgkin's disease. Hematol Oncol Clin North Am 7:368-387
24. Henry-Amar M, Aeppli DM, Anderson J (1990) Workshop statistical report. Part XI. Study of second cancer risk. Collog Inserm 196:355-367
25. Kaldor JM, Day NE, Band P, Choi NW, Clarke EA, Coleman MP, Hakama M, Koch M, Langmark F, Neal FE (1987) Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: an international collaborative study among cancer registries. Int J Cancer 39:571-585
26. Kaldor JM, Day NE, Clarke A, Van Leeuwen FE, Henry-Amar M, Fiorentino MV, Bell J, Pedersen D, Band P, Avonline D (1990a) Leukemia following Hodgkin's disease. N Engl J Med 322:7-13
27. Karakas T, Rummel M, Bergmann L, Hoelzer D, Mitrou P (1997) Secondary malignancies following treatment of malignant lymphomas with etoposide-containing chemotherapy. Proc Am Soc Clin Oncol 24a (abstract 82)
28. Lowsky R, Lipton J, Fyles G, Minden M, Meharchand J, Tegpar J, Atkins H, Sutcliffe S, Messner H (1994) Secondary malignancies after bone marrow transplantation in adults. J Clin Oncol 12:2187-2192
29. Mauch PM, Kalish LA, Marcus KC, Coleman CN, Shulman LN, Krill E, Come S, Silver B, Canellos GP, Torbell NJ (1996) Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome. Blood 87:3625-3632
30. Miller J, Arthur D, Litz C, Neglia J, Miller W, Weisdorf D (1994) Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood 12:3780-3786
31. Nelson DF, Cooper S, Weston M, Rubin P (1981) Second malignant neoplasms in patients treated for Hodgkin's disease with radiotherapy or radiotherapy and chemotherapy. Cancer 48:2286-2393
32. Nichols C, Breeden E, Loehrer P, Williams S, Einhorn LH (1993) Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols. J Natl Cancer Inst 85:36-40
33. Pedersen-Bjergaard J, Ersboll J, Sorensen HM, Keiding N, Larson SO, Philip P, Larsen MS, Schultz H, Nissen NJ (1985) Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophophamide for non-Hodgkin's lymphomas. Ann Intern Med 103:195-200
34. Pedersen-Bjergaard J, Philip P, Larson SO, Jensen G, Bryting K (1990) Chromosome aberrations and prognostic factors in therapy related myelodysplasia and acute nonlymphocytic leukemia. Blood 6:1083-1091
35. Pedersen-Bjergaard J, Daugaard G, Werner-Hansen S, Philip P, Larsen OS, Rorth M (1991) Increased risk of myelodysplasia and leukemia after etoposide, cisplatin and bleomycin for germ-cell tumours. Lancet 338:159-363
36. Portugal MA, Falkson HC, Stevens K, Falkson G (1979) Acute-leukemia as a complication of long-term treatment of advanced breast cancer. Cancer Treat Rep 63:177-181
37. Pui CH, Ribeiro C, Hancock ML, Rivera GK, Evans WE, Raumondi SC, Head DR, Behr FG, Mahmond MH, Sandlund JT (1991) Acute myeloid leukemia in children treated with epipodopyllotoxins for acute lymphoblastic leukemia. N Engl J Med 325:1682-1687
38. Sajeva M, Musto P, Melillo L, Cascavilla N, Perla G, DÀrena G, Carotenuto M (1997) Secondary acute myeloid leukemia (s-AML) after 3M (mitoxantrone, methotrexate, mitomycin) chemotherapy for metastasic breast cancer: report of three cases. Proc Am Soc Clin Oncol 189a (abstract 664)
39. Shipp MA, Harrington DP, Klatt MM, Jochelson MS, Pinkus GS, Marshall IL, Rosenthal DS, Skarin AT, Canellos GP (1986) Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or m-BACOD. Ann Intern Med 104:757-761
40. Socie G, Henry-Amar M, Bagigalupo A, Hows J, Tichelli A, Ljungman P, McCann S, Friekhofen N, Van't Veer-Korthof E, Gluckman E (1993) Malignant tumours occuring after treatment of aplastic anemia. N Engl J Med 329:1152-1157
41. Stone R (1994) Myelodysplastic syndrome after autologous transplantation for lymphoma: the price of progress? Blood 83:3437-3440
42. Stone R, Neuberg D, Soiffer R, Takvorian T, Whelan M, Rabinowe S, Aster J, Learitt P, Mauch P, Freedman A, Nadler L (1994) Myelodysplastic syndrome as a complication after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 12:2535-2542
43. Travis LB, Curtis RE, Stovall M, Holowaty EJ, Van Leeuwen FE, Glimelius B, Lynch CF, Hagenbeeck A, Li Ch-Y, Banks PM, Gospodarowicz MK, Adami J, Wacholder S, Inskip PD, Tucker MA, Boice JD Jr (1994) Risk of leukemia following treatment for non-Hodgkin's lymphoma. J Natl Cancer Inst 86:1450-1457
44. Travis LB, Weeks J, Curtis RE, Chaffey JT, Stovall M, Banks PM, Boice JB Jr (1996) Leukemia following low-dose irradiation and chemotherapy for non-Hodgkin's lymphoma. J Clin Oncol 14:565-571
45. Traweek S, Slovak M, Nademanee A, Brynes R, Niland J, Forman S (1993) Myelodysplasia occuring after autologous bone marrow transplantation (ABMT) for Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL). (abstract) Blood 82:455a
46. Tucker MA, Coleman CN, Cox RS, Varghese A, Rosenbery SA (1988) Rush of second cancers after treatment of Hodgkin's disease. N Engl J Med 318:76-81
47. Valagussa P, Moliterni A, Terenziani M, Zambetti M, Bonadonna G (1994) Second malignancies following CMF-based adjuvant chemotherapy in resecable breast cancer. Ann Oncol 5:803-808
48. Van der Velden JW, Van Pullen WL, Guinee VF, Pfeinffer R, van Leeuwen FS, van der Linden EA, Vardomskaya J, Lane W, Durand W, Lagarde C (1988) Subsequent development of acute non-lymphocytic leukemia in patients treated for Hodkin's disease. Int J Cancer 42:252-255
49. Van Leeuwen FE, Somers R, Taal B (1989) Increased risk of lung cancer, non-Hodgkin's lymphoma, and leukemia following Hodgkin's disease. J Clin Oncol 7:1046-1052
50. Van Leeuwen FE, Stiggelbout AM, Belt-Dusenbaut AW van den, Noyon R, Eliel MR, Kerkhoff EH van, Delemarre JF, Somers R (1993) Second cancer risk following testicular cancer. J Clin Oncol 11:415-424
51. Van Leeuwen FE, Klohman WJ, Hagenbeeck A, Noyon R, Belt-Dusebout AW van den, Kerkhoff EH van, Heerde P van, Somers R (1994a) Second cancer risk following Hodgkin's disease: a 20 year follow-up-study. J Clin Oncol 12:312-325
52. Van Leeuwen FE, Chorus AM, Belt-Dusebout A van den, Hagenbeeck A, Noyon R, Kerkhoff E van, Pinedo H, Somers R (1994b) Leukemia risk following Hodgkin's disease: relation of cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol 12:1063-1073
53. Witherspoon R, Fisher L, Schoch G, Martin P, Sullivan K, Sanders J, Deeg J, Doney K, Thomas D, Storb R, Thomas E (1989) Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med 321:784-789
54. Whitlock JA, Greer JP, Lukas JN (1991). Epipodophyllotoxin-related leukemia. Cancer 68:600-604